Angitia Biopharmaceuticals has announced the closing of a USD 130 million Series D financing round. Frazier Life Sciences and Venrock Healthcare Capital Partners co-led the financing, with participation from new investors: Ascenta Capital, certain funds and accounts managed by Blackrock, BVF Partners, Logos Capital, RA Capital Management and Wellington Management. Existing investors, Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment, Hillhouse Investment, Legend Capital, Morningside Group, OrbiMed, TF Capital and Yonghua Capital also participated. Proceeds from the Series D will support the continued development of Angitia’s robust pipeline of novel, differentiated investigational treatments for serious musculo-skeletal diseases.

“This financing underscores the continued growth of Angitia, the quality of our emerging data, and the advancement of our clinical product candidates, as recently demonstrated with the completion of enrollment in our phase-II ARTEMIS trial in postmenopausal osteoporosis and the initiation of dosing in our phase-II IDUN trial in osteogenesis imperfect. We are excited and grateful to add another strong set of high-quality investors to our growing syndicate,” said Dr David Ke, MD, Chief Executive Officer, Angitia.

In connection with the financing, Kevin Li, MD, a Partner on the Frazier Life Sciences team, will join the Board of Directors. Dr Li was previously a resident physician in Internal Medicine at Stanford University and a consultant at McKinsey & Company, where he focused on corporate strategy, growth and M&A in the hospital services and pharmaceutical industries. Dr Li received his MD from Stanford University and his BS from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry, and was a member of Phi Beta Kappa.